Robert W. Baird Raises Climb Bio (NASDAQ:CLYM) Price Target to $12.00

Climb Bio (NASDAQ:CLYM) had its target price upped by stock analysts at Robert W. Baird from $9.00 to $12.00 in a research note issued on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s target price indicates a potential upside of 67.13% from the stock’s current price.

CLYM has been the topic of a number of other reports. Wedbush initiated coverage on shares of Climb Bio in a research report on Thursday. They issued an “outperform” rating and a $12.00 price target on the stock. Piper Sandler assumed coverage on shares of Climb Bio in a research note on Friday, February 13th. They issued an “overweight” rating for the company. HC Wainwright lifted their price target on shares of Climb Bio from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Climb Bio in a report on Wednesday, January 21st. Finally, Wall Street Zen cut shares of Climb Bio from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 8th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Climb Bio currently has an average rating of “Moderate Buy” and a consensus price target of $10.60.

Climb Bio Price Performance

NASDAQ CLYM opened at $7.18 on Friday. The company’s fifty day moving average is $5.20 and its two-hundred day moving average is $3.32. The firm has a market capitalization of $489.53 million, a price-to-earnings ratio of -8.07 and a beta of -0.25. Climb Bio has a 52-week low of $1.05 and a 52-week high of $7.59.

Climb Bio (NASDAQ:CLYM) last posted its quarterly earnings results on Thursday, March 5th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06). As a group, sell-side analysts expect that Climb Bio will post -1.57 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Ra Capital Management, L.P. bought 213,099 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The shares were acquired at an average price of $2.18 per share, with a total value of $464,555.82. Following the transaction, the director owned 3,294,856 shares in the company, valued at $7,182,786.08. This represents a 6.91% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders bought 321,672 shares of company stock worth $779,626 in the last ninety days. 0.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Climb Bio

Several large investors have recently made changes to their positions in CLYM. MPM Bioimpact LLC acquired a new stake in shares of Climb Bio in the fourth quarter valued at approximately $10,686,000. Price T Rowe Associates Inc. MD raised its position in shares of Climb Bio by 265.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,923,639 shares of the company’s stock valued at $7,695,000 after purchasing an additional 1,396,722 shares during the period. ADAR1 Capital Management LLC lifted its stake in shares of Climb Bio by 972.8% during the 4th quarter. ADAR1 Capital Management LLC now owns 1,432,475 shares of the company’s stock worth $5,730,000 after buying an additional 1,298,945 shares during the last quarter. Sphera Funds Management LTD. lifted its stake in shares of Climb Bio by 114.4% during the 4th quarter. Sphera Funds Management LTD. now owns 932,247 shares of the company’s stock worth $3,729,000 after buying an additional 497,410 shares during the last quarter. Finally, Nan Fung Trinity HK Ltd. bought a new stake in shares of Climb Bio during the 2nd quarter worth about $575,000. Institutional investors and hedge funds own 69.76% of the company’s stock.

Key Headlines Impacting Climb Bio

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Wedbush initiated coverage with an “outperform” rating and a $12 price target, providing analyst endorsement that implies significant upside from current levels. Wedbush Initiates Coverage
• Positive Sentiment: Robert W. Baird raised its price target from $9 to $12 and assigned an “outperform” rating, echoing bullish analyst sentiment and adding upward price-target momentum. Baird Price Target Raise
• Positive Sentiment: Company operational update: dosing completed in a Phase 1 subcutaneous study of budoprutug, multiple clinical trials ongoing (pMN, ITP, SLE) with initial data expected H1–H2 2026, ongoing enrollment in CLYM116 Phase 1; management says cash runway extends into 2028 — these milestones support medium-term value if data readouts are positive. Press Release
• Neutral Sentiment: Short-interest reports in early March show zero reported short positions and a 0.0 days-to-cover figure, which appears to be a data anomaly (NaN/inconsistent reporting) and likely has limited informational value until clarified.
• Negative Sentiment: Climb reported Q4 EPS of ($0.26), missing the consensus ($0.20) by $0.06 — a clear near-term negative that likely pressured the stock as investors digest lower-than-expected profitability metrics. Earnings Release

About Climb Bio

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.